Stock LGND LIGAND PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
70.57 USD +0.28% Intraday chart for Ligand Pharmaceuticals Incorporated -2.62% -1.19%
Apr. 08 Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference CI
Apr. 03 Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,832 1,599 2,581 1,128 1,245 1,267 - -
Enterprise Value (EV) 1 1,832 1,599 2,581 1,128 1,245 1,267 1,267 1,267
P/E ratio 3.27 x -553 x 46.2 x -33.7 x 24.3 x 42.2 x 24.7 x -
Yield - - - - - - - -
Capitalization / Revenue 15.2 x 8.58 x 9.31 x 5.75 x 9.48 x 9.23 x 8.04 x 6.6 x
EV / Revenue 15.2 x 8.58 x 9.31 x 5.75 x 9.48 x 9.23 x 8.04 x 6.6 x
EV / EBITDA 29.3 x 20 x 15.7 x 12.9 x 17.7 x 12.3 x 9.56 x -
EV / FCF -57.4 x 31.9 x 36.9 x 9.41 x 27 x 25.8 x 16.3 x 17.4 x
FCF Yield -1.74% 3.13% 2.71% 10.6% 3.7% 3.88% 6.15% 5.75%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 17,563 16,081 16,712 16,894 17,436 17,958 - -
Reference price 2 104.3 99.45 154.5 66.80 71.42 70.57 70.57 70.57
Announcement Date 2/6/20 2/3/21 2/17/22 2/22/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 120.3 186.4 277.1 196.2 131.3 137.3 157.6 192.1
EBITDA 1 62.52 79.99 164.9 87.8 70.29 103.2 132.6 -
EBIT 1 -5.721 25.84 78.9 3.037 11.94 23.2 55.86 52.82
Operating Margin -4.76% 13.86% 28.47% 1.55% 9.09% 16.89% 35.44% 27.5%
Earnings before Tax (EBT) 1 796.6 -10.54 47.3 36.01 63.66 36.49 67.09 -
Net income 1 629.3 -2.985 57.59 -33.36 52.15 28.54 52.54 -
Net margin 523.19% -1.6% 20.78% -17% 39.72% 20.78% 33.33% -
EPS 2 31.85 -0.1800 3.340 -1.980 2.940 1.673 2.860 -
Free Cash Flow 1 -31.89 50.13 70.04 119.9 46.06 49.17 77.94 72.85
FCF margin -26.51% 26.89% 25.27% 61.11% 35.07% 35.8% 49.44% 37.93%
FCF Conversion (EBITDA) - 62.67% 42.47% 136.59% 65.52% 47.65% 58.78% -
FCF Conversion (Net income) - - 121.62% - 88.31% 172.29% 148.35% -
Dividend per Share - - - - - - - -
Announcement Date 2/6/20 2/3/21 2/17/22 2/22/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 64.84 72.47 45.69 57.42 66.09 50.38 43.98 26.37 32.87 28.1 27.92 33.2 35.85 40.37
EBITDA 1 37.1 34.85 11.46 22.3 24.96 16.07 28.18 14.72 14.98 10.68 16.27 24.44 29.11 33.36
EBIT 1 15.71 12.73 -9.306 -0.469 0.636 -20.1 14.2 -1.983 -0.122 -3.358 -1.511 4.371 8.332 12.01
Operating Margin 24.22% 17.57% -20.37% -0.82% 0.96% -39.89% 32.3% -7.52% -0.37% -11.95% -5.41% 13.17% 23.24% 29.74%
Earnings before Tax (EBT) 1 15.26 -7.026 -20.14 -0.636 0.857 24.14 55.54 3.171 -15.34 17.1 3.044 8.182 10.98 14.31
Net income 1 13.72 -4.968 -15.38 -0.895 0.404 -17.48 41.95 2.29 -12.79 18.19 2.36 6.236 8.588 11.38
Net margin 21.17% -6.85% -33.67% -1.56% 0.61% -34.7% 95.38% 8.69% -38.92% 64.72% 8.45% 18.79% 23.96% 28.18%
EPS 2 0.8000 -0.3000 -0.9100 -0.0500 0.0200 -1.040 2.330 0.1300 -0.7400 1.030 0.2267 0.4000 0.4867 0.5533
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/9/21 2/17/22 5/4/22 8/8/22 11/7/22 2/22/23 5/4/23 8/8/23 11/8/23 2/27/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -31.9 50.1 70 120 46.1 49.2 77.9 72.9
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 2.55 4.46 8.76 17.9 3.52 5 5 5.1
Capex / Sales 2.12% 2.39% 3.16% 9.13% 2.68% 3.64% 3.17% 2.66%
Announcement Date 2/6/20 2/3/21 2/17/22 2/22/23 2/27/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
70.57 USD
Average target price
116.8 USD
Spread / Average Target
+65.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LIGAND PHARMACEUTICALS INCORPORATED Stock Ligand Pharmaceuticals Incorporated
-1.19% 1.27B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LGND Stock
  4. Financials Ligand Pharmaceuticals Incorporated